Terns Pharmaceuticals’ stock surged after its experimental obesity drug, TERN-601, demonstrated promising weight loss results in a Phase I study. The drug showed dose-dependent weight reduction and a favorable safety profile, prompting the company to initiate a Phase II trial in 2025.